# Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA

> **NCT02811354** · PHASE2 · UNKNOWN · sponsor: **National University Hospital, Singapore** · enrollment: 108 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** AZD9291

## Key facts

- **NCT ID:** NCT02811354
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-02-24
- **Primary completion:** 2019-02-24
- **Final completion:** 2020-02-24
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2018-09-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02811354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02811354, "Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02811354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*